Company Overview
Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company dedicated to the development of intranasal drugs designed to treat emergency medical conditions. The company functions within the Healthcare sector, specifically within the Drug Manufacturers - General industry, which implies a focus on the research and production of pharmaceutical agents rather than consumer healthcare services or medical devices. The company's current market capitalization stands at $25.88M, while its annual revenue and employee count are not disclosed in the available financial data. These valuation figures indicate that Nasus Pharma is a small-cap entity operating with a relatively modest scale compared to large-cap pharmaceutical peers, suggesting a stage of development where resources are likely concentrated on clinical progression rather than broad commercial distribution.
Financial Health
The company reports a net income of $-5,805,000 for the trailing twelve months, while revenue and EBITDA figures are not available for public reporting. The significant gap between the reported net income loss and the unavailable revenue data suggests a cost structure where operating expenses, likely driven by clinical trial costs and research and development, substantially exceed current revenue generation. Free cash flow is reported at $-3,484,000, which indicates that the company is burning cash to fund its operations and development pipeline, thereby limiting its immediate financial flexibility and reliance on external capital sources. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, a level that typically indicates that the company has not yet achieved commercial profitability or that costs are fully absorbed by revenue, resulting in no measurable margin expansion at this stage. The company holds $4.29M in cash against $118,000 in debt, resulting in a debt-to-equity ratio of 4.26, which reveals a highly leveraged balance sheet structure where equity is significantly diluted relative to obligations, though the low absolute debt amount mitigates immediate solvency concerns. The current ratio is 2.25, indicating that the company possesses 2.25 times the liquid assets necessary to cover its short-term liabilities, which points to adequate short-term liquidity management despite the cash burn rate. Return on Equity is not available due to the lack of positive earnings, while Return on Assets stands at -107.1%, a metric that reveals management is currently destroying value relative to the asset base rather than generating returns, a common characteristic of early-stage clinical entities.
Valuation Assessment
The trailing P/E ratio and forward P/E ratio are both listed as N/A, a status that implies the stock does not trade on an earnings basis and that the market cannot value the stock based on traditional earnings multiples due to the company's negative earnings trajectory. The price-to-book ratio is 7.20, a figure that indicates the market is pricing the company at a significant premium over its tangible book value, reflecting high expectations for future asset appreciation or successful drug approvals that could transform the company's valuation. The price-to-sales ratio and EV/EBITDA are also N/A, suggesting that these alternative valuation metrics are not applicable given the lack of positive earnings or sales data, forcing investors to rely primarily on asset-based or clinical-stage valuation methodologies. The 52-week high is $9.99 and the 52-week low is $2.14, meaning the stock has experienced substantial volatility over the past year. Without a specific current price provided in the facts to calculate a precise percentage, the stock's position is defined by this wide trading range, illustrating the high risk and reward profile typical of clinical-stage biotech firms. The beta value is not available, which prevents a direct comparison of the stock's price volatility relative to the broader market, though the wide 52-week range of $9.99 down to $2.14 inherently suggests high idiosyncratic risk independent of market beta.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year rates are both N/A, indicating that historical growth trends cannot be calculated from the current financial dataset. Consequently, it is impossible to determine whether earnings are growing faster or slower than revenue, as neither metric currently supports a comparative growth analysis. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. This non-dividend status implies that Nasus Pharma reinvests all available earnings, or rather its limited cash reserves, directly into its growth initiatives such as drug development and clinical trials rather than returning capital to investors. The overall growth and income profile is characterized by a complete absence of dividend income and undefined historical growth rates, positioning the stock as a pure-play growth vehicle dependent entirely on future clinical milestones rather than current cash flow or dividend generation.